文献速递胸部肿瘤放疗姑息放疗与转移瘤

非小细胞肺癌免疫治疗进展后放疗的远隔效应与生存分析

Radiotherapy in patients with NSCLC developing progressive disease during immune checkpoint inhibition: Abscopal responses and survival.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-02-11

多因素分析显示放疗开始时ECOG评分和寡转移性疾病与总生存改善显著相关。

要点

  • ICI进展后放疗可在部分NSCLC患者中诱导远隔效应,可能延迟全身治疗转换。
  • 放疗开始时ECOG评分和寡转移性疾病与总生存改善显著相关。
  • 年龄较大与远隔进展发生率较高相关,男性显示远隔进展风险升高趋势。

核心结论

  • 放疗能够在部分ICI治疗下进展的NSCLC患者中诱导远隔效应,可能延迟全身治疗的转换。
  • 远隔获益在老年患者和男性中较少见。

研究设计与样本

  • ARTIC(ARO 2022-10,DRKS00032390)为多中心回顾性研究,分析接受ICI期间或之后因进展接受放疗的NSCLC患者。

主要发现

  • 逻辑回归分析中,年龄较大与远隔进展发生率较高相关(OR:1.07,95%-CI:1.00-1.14;p=0.05)。
  • 男性显示远隔进展风险升高趋势(OR=3.13;95%-CI:0.93-11.86;p=0.075)。
  • 多因素Cox分析中,放疗开始时ECOG体能评分(HR:0.29,95%-CI:0.12-0.69;p<0.01)和寡转移性疾病(HR:0.34,95%-CI:0.12-0.94;p=0.039)与总生存改善显著相关。

临床怎么用

  • 对于ICI治疗期间或之后进展的NSCLC患者,可考虑对进展病灶进行放疗以诱导远隔效应并可能延迟全身治疗转换。
  • 放疗开始时ECOG评分较好和寡转移性疾病患者可能从放疗中获得更长的总生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Increasing evidence suggests that RT and ICI have synergistic effects on anti-tumor immune response, and abscopal responses (AR) have been described more frequently with this combination. Here, we analyzed the frequency and factors associated with AR in NSCLC patients receiving ICI and RT. METHODS: In ARTIC (ARO 2022-10, DRKS00032390), a multicenter, retrospective study, patients treated with RT for progressive disease during or after receiving ICI were analyzed for abscopal benefit (AB) and overall survival (OS). Patients were grouped by non-irradiated lesion response; logistic and Cox regression were used to analyze factors linked to AR, AB, and OS. RESULTS: Fifty-six patients from 13 centers with 137 non-irradiated lesions were analyzed. Most received hypofractionated or stereotactic RT. The most common RT sites were lung, bone, and brain. Thirty-three patients showed AB, with 15 patients developing an AR in at least one non-irradiated lesion. In the logistic regression analysis, older age was associated with a higher rate of AP (odds ratio (OR): 1.07, 95%-CI: 1.00-1.14; p = 0.05). Male sex showed a trend towards higher risk of AP (OR = 3.13; 95%- CI: 0.93-11.86; p = 0.075). In the multivariable Cox analysis, ECOG performance score at the start of RT (hazard ratio (HR): 0.29, 95%-CI: 0.12-0.69; p < 0.01) and oligometastatic disease (HR: 0.34, 95%-CI: 0.12-0.94; p = 0.039) were significantly associated with improved OS. CONCLUSION: RT was able to induce AR in some NSCLC patients who were progressive under ICI, possibly delaying a switch in systemic treatment. AB was less frequent in older patients and in men.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kaufmann J, Trommer M, Rühle A, et al. Radiotherapy in patients with NSCLC developing progressive disease during immune checkpoint inhibition: Abscopal responses and survival. Clin Transl Radiat Oncol. 2026. PMID: 41815721. doi:10.1016/j.ctro.2026.101125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。